Busulfan with 400 centigray of total body irradiation and higher dose fludarabine: An alternative regimen for hematopoietic stem cell transplantation in pediatric acute lymphoblastic leukemia.
acute lymphoblastic leukemia
allogeneic transplant
busulfan
fludarabine
low-dose radiation
pediatric
Journal
Pediatric blood & cancer
ISSN: 1545-5017
Titre abrégé: Pediatr Blood Cancer
Pays: United States
ID NLM: 101186624
Informations de publication
Date de publication:
12 Jan 2024
12 Jan 2024
Historique:
revised:
01
12
2023
received:
03
09
2023
accepted:
21
12
2023
medline:
13
1
2024
pubmed:
13
1
2024
entrez:
13
1
2024
Statut:
aheadofprint
Résumé
Hematopoietic stem cell transplantation can be curative for children with difficult-to-treat leukemia. The conditioning regimen utilized is known to influence outcomes. We report outcomes of the conditioning regimen used at the Alberta Children's Hospital, consisting of busulfan (with pharmacokinetic target of 3750 μmol*min/L/day ±10%) for 4 days, higher dose (250 mg/m This retrospective study involved children receiving transplant for acute lymphoblastic leukemia (ALL). It compared children who fell within the target range for busulfan with those who were either not measured or were measured and fell outside this range. All other treatment factors were identical. Twenty-nine children (17 within target) were evaluated. All subjects engrafted neutrophils with a median [interquartile range] time of 14 days [8-30 days]. The cumulative incidence of acute graft-versus-host disease was 44.8% [95% confidence interval, CI: 35.6%-54.0%], while chronic graft-versus-host disease was noted in 16.0% [95% CI: 8.7%-23.3%]. At 2 years, the overall survival was 78.1% [95% CI: 70.8%-86.4%] and event-free survival was 74.7% [95% CI: 66.4%-83.0%]. Cumulative incidence of relapse was 11.3% [95% CI: 5.1%-17.5%]. There were no statistically significant differences in between the group that received targeted busulfan compared with the untargeted group. Our conditioning regiment for children with ALL resulted in outcomes comparable to standard treatment with acceptable toxicities and significant reduction in radiation dose. Targeting busulfan dose in this cohort did not result in improved outcomes.
Sections du résumé
BACKGROUND
BACKGROUND
Hematopoietic stem cell transplantation can be curative for children with difficult-to-treat leukemia. The conditioning regimen utilized is known to influence outcomes. We report outcomes of the conditioning regimen used at the Alberta Children's Hospital, consisting of busulfan (with pharmacokinetic target of 3750 μmol*min/L/day ±10%) for 4 days, higher dose (250 mg/m
PROCEDURE
METHODS
This retrospective study involved children receiving transplant for acute lymphoblastic leukemia (ALL). It compared children who fell within the target range for busulfan with those who were either not measured or were measured and fell outside this range. All other treatment factors were identical.
RESULTS
RESULTS
Twenty-nine children (17 within target) were evaluated. All subjects engrafted neutrophils with a median [interquartile range] time of 14 days [8-30 days]. The cumulative incidence of acute graft-versus-host disease was 44.8% [95% confidence interval, CI: 35.6%-54.0%], while chronic graft-versus-host disease was noted in 16.0% [95% CI: 8.7%-23.3%]. At 2 years, the overall survival was 78.1% [95% CI: 70.8%-86.4%] and event-free survival was 74.7% [95% CI: 66.4%-83.0%]. Cumulative incidence of relapse was 11.3% [95% CI: 5.1%-17.5%]. There were no statistically significant differences in between the group that received targeted busulfan compared with the untargeted group.
CONCLUSION
CONCLUSIONS
Our conditioning regiment for children with ALL resulted in outcomes comparable to standard treatment with acceptable toxicities and significant reduction in radiation dose. Targeting busulfan dose in this cohort did not result in improved outcomes.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e30844Informations de copyright
© 2024 Wiley Periodicals LLC.
Références
Hunger SP, Mullighan CG. Acute lymphoblastic leukemia in children. N Engl J Med. 2015;373(16):1541-1552. doi:10.1056/NEJMra1400972
Peters C, Schrappe M, von Stackelberg A, et al. Stem-cell transplantation in children with acute lymphoblastic leukemia: a prospective international multicenter trial comparing sibling donors with matched unrelated donors-the ALL-SCT-BFM-2003 trial. J Clin Oncol. 2015;33(11):1265-1274. doi:10.1200/JCO.2014.58.9747
Ishaqi MK, Afzal S, Dupuis A, Doyle J, Gassas A. Early lymphocyte recovery post-allogeneic hematopoietic stem cell transplantation is associated with significant graft-versus-leukemia effect without increase in graft-versus-host disease in pediatric acute lymphoblastic leukemia. Bone Marrow Transplant. 2008;41(3):245-252. doi:10.1038/sj.bmt.1705891
Pulsipher M, Peters C, Pui C. High-risk pediatric acute lymphoblastic leukemia: to transplant or not to transplant? Biol Blood Marrow Transplant. 2011;17:S137-S148. doi:10.1016/j.bbmt.2010.10.005
Sakellari I, Gavriilaki E, Chatziioannou K, et al. Long-term outcomes of total body irradiation plus cyclophosphamide versus busulfan plus cyclophosphamide as conditioning regimen for acute lymphoblastic leukemia: a comparative study. Ann Hematol. 2018;97(10):1987-1994. doi:10.1007/s00277-018-3383-9
Thomas ED, Buckner CD, Banaji M, et al. One hundred patients with acute leukemia treated by chemotherapy, total body irradiation, and allogeneic marrow transplantation. Blood. 1977;49(4):511-533.
Peters C, Dalle JH, Locatelli F, et al. Total body irradiation or chemotherapy conditioning in childhood ALL: a multinational, randomized, noninferiority phase III study. J Clin Oncol. 2021;39(4):295-307. doi:10.1200/JCO.20.02529
Ciurea SO, Andersson BS. Busulfan in hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2009;15(5):523-536. doi:10.1016/j.bbmt.2008.12.489
Bunin N, Aplenc R, Kamani N, Shaw K, Cnaan A, Simms S. Randomized trial of busulfan vs total body irradiation containing conditioning regimens for children with acute lymphoblastic leukemia: a pediatric blood and marrow transplant consortium study. Bone Marrow Transplant. 2003;32(6):543-548. doi:10.1038/sj.bmt.1704198
Vassal G, Michel G, Espérou H, et al. Prospective validation of a novel IV busulfan fixed dosing for paediatric patients to improve therapeutic AUC targeting without drug monitoring. Cancer Chemother Pharmacol. 2008;61(1):113-123. doi:10.1007/s00280-007-0455-2
Tse WT, Duerst R, Schneiderman J, Chaudhury S, Jacobsohn D, Kletzel M. Age-dependent pharmacokinetic profile of single daily dose i.v. busulfan in children undergoing reduced-intensity conditioning stem cell transplant. Bone Marrow Transplant. 2009;44(3):145-156. doi:10.1038/bmt.2008.437
Schechter T, Finkelstein Y, Doyle J, et al. Pharmacokinetic disposition and clinical outcomes in infants and children receiving intravenous busulfan for allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2007;13(3):307-314. doi:10.1016/j.bbmt.2006.10.026
Dupuis LL, Najdova M, Saunders EF. Retrospective appraisal of busulfan dose adjustment in children [published correction appears in Bone Marrow Transplant. 2003;31(8):729]. Bone Marrow Transplant. 2000;26(11):1143-1147. doi:10.1038/sj.bmt.1702700
Wall DA, Chan KW, Nieder ML, et al. Safety, efficacy, and pharmacokinetics of intravenous busulfan in children undergoing allogeneic hematopoietic stem cell transplantation. Pediatr Blood Cancer. 2010;54(2):291-298. doi:10.1002/pbc.22227
Russell JA, Tran HT, Quinlan D, et al. Once-daily intravenous busulfan given with fludarabine as conditioning for allogeneic stem cell transplantation: study of pharmacokinetics and early clinical outcomes. Biol Blood Marrow Transplant. 2002;8(9):468-476. doi:10.1053/bbmt.2002.v8.pm12374451
Pierce G, Balogh A, Frederick R, Gordon D, Yarschenko A, Hudson A. Extended SSD VMAT treatment for total body irradiation. J Appl Clin Med Phys. 2019;20(1):200-211. doi:10.1002/acm2.12519
Glucksberg H, Storb R, Fefer A, et al. Clinical manifestations of graft-versus-host disease in human recipients of marrow from HL-A-matched sibling donors. Transplantation. 1974;18(4):295-304. doi:10.1097/00007890-197410000-00001
Jagasia MH, Greinix HT, Arora M, et al. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. The 2014 Diagnosis and Staging Working Group report. Biol Blood Marrow Transplant. 2015;21(3):389-401.e1. doi:10.1016/j.bbmt.2014.12.001
Russell JA, Savoie ML, Balogh A, et al. Allogeneic transplantation for adult acute leukemia in first and second remission with a novel regimen incorporating daily intravenous busulfan, fludarabine, 400 cGy total-body irradiation, and thymoglobulin. Biol Blood Marrow Transplant. 2007;13(7):814-821. doi:10.1016/j.bbmt.2007.03.003
Savoie ML, Balogh A, Chaudhry MA, et al. Total body irradiation (TBI) added to fludarabine/busulfan/antithymocyte globulin (FLUBUP/ATG) conditioning increases overall survival and relapse-free survival in patients with acute myeloid leukemia (AML) receiving allogeneic stem cell transplants. Blood. 2006;108(11):3010. doi:10.1182/blood.V108.11.3010.3010
Handgretinger R, Lang P. Could (should) we abandon total body irradiation for conditioning in children with leukemia. Blood Rev. 2022;56:100966. doi:10.1016/j.blre.2022.100966
Khan AF, Xu Y, Fidler-Benaoudia M, Diaz R, Logie N. Long-term morbidity of children receiving hematopoietic stem cell transplant with total body irradiation conditioning for hematologic malignancies. Int J Radiat Oncol Biol Phys. 2022;114(5):1075. doi:10.1016/j.ijrobp.2022.09.044
Baker KS, Leisenring WM, Goodman PJ, et al. Total body irradiation dose and risk of subsequent neoplasms following allogeneic hematopoietic cell transplantation. Blood. 2019;133(26):2790-2799. doi:10.1182/blood.2018874115
Chaudhury S, Helenowski I, Duerst R, et al. Reduced toxicity myeloablative conditioning regimen in pediatric hematologic malignancies not associated with improved outcomes. Physicians-Poster Session. Bone Marrow Transplant. 2017;52:S124-S516. doi:10.1038/bmt.2017.134
Rossoff J, Jacobsohn D, Kwon S, et al. Reduced-toxicity conditioning regimen with busulfan, fludarabine, rATG, and 400 cGy TBI in pediatric patients undergoing hematopoietic stem cell transplant for high-risk hematologic malignancies. Pediatr Blood Cancer. 2021;68(8):e29087. doi:10.1002/pbc.29087
Langenhorst JB, van Kesteren C, van Maarseveen EM, et al. Fludarabine exposure in the conditioning prior to allogeneic hematopoietic cell transplantation predicts outcomes. Blood Adv. 2019;3(14):2179-2187. doi:10.1182/bloodadvances.2018029421
Dekker L, Calkoen FG, Jiang Y, et al. Fludarabine exposure predicts outcome after CD19 CAR T-cell therapy in children and young adults with acute leukemia. Blood Adv. 2022;6(7):1969-1976. doi:10.1182/bloodadvances.2021006700
Beitinjaneh A, McKinney A, Cao Q, Weisdorf DJ. Fludarabine-associated neurotoxicity after hematopoietic cell transplantation (HCT): clinical and radiographic features predict outcome. Blood. 2009;114(22):2270. doi:10.1182/blood.V114.22.2270.2270
Yeh AC, O'Donnell PV, Schoch G, et al. Long-term survival with mixed chimerism in patients with AML and MDS transplanted after conditioning with targeted busulfan, fludarabine, and thymoglobulin. Bone Marrow Transplant. 2022;57(2):198-206. doi:10.1038/s41409-021-01518-0
Rustia E, Violago L, Jin Z, et al. Risk factors and utility of a risk-based algorithm for monitoring cytomegalovirus, epstein-barr virus, and adenovirus infections in pediatric recipients after allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2016;22(9):1646-1653. doi:10.1016/j.bbmt.2016.05.014
Rowe RG, Guo D, Lee M, Margossian S, London WB, Lehmann L. Cytomegalovirus infection in pediatric hematopoietic stem cell transplantation: risk factors for primary infection and cases of recurrent and late infection at a single center. Biol Blood Marrow Transplant. 2016;22(7):1275-1283. doi:10.1016/j.bbmt.2016.04.004
Willasch AM, Peters C, Sedláček P, et al. Myeloablative conditioning for allo-HSCT in pediatric ALL: fTBI or chemotherapy?-A multicenter EBMT-PDWP study [published correction appears in Bone Marrow Transplant. 2021;56(10):2615]. Bone Marrow Transplant. 2020;55(8):1540-1551. doi:10.1038/s41409-020-0854-0
Modi D, Singh V, Kim S, et al. Comparison of myeloablative and reduced intensity conditioning unrelated donor allogeneic peripheral blood stem cell transplant outcomes for AML using thymoglobulin for GvHD prophylaxis. Ann Hematol. 2021;100(4):969-978. doi:10.1007/s00277-021-04445-8
Eapen M, Logan BR, Confer DL, et al. Peripheral blood grafts from unrelated donors are associated with increased acute and chronic graft-versus-host disease without improved survival. Biol Blood Marrow Transplant. 2007;13(12):1461-1468. doi:10.1016/j.bbmt.2007.08.006
Amouzegar A, Dey BR, Spitzer TR. Peripheral blood or bone marrow stem cells? Practical considerations in hematopoietic stem cell transplantation. Transfus Med Rev. 2019;33(1):43-50. doi:10.1016/j.tmrv.2018.11.003
Anasetti C, Logan BR, Lee SJ, et al. Peripheral-blood stem cells versus bone marrow from unrelated donors. N Engl J Med. 2012;367(16):1487-1496. doi:10.1056/NEJMoa1203517
Pulsipher MA, Langholz B, Wall DA, et al. Risk factors and timing of relapse after allogeneic transplantation in pediatric ALL: for whom and when should interventions be tested. Bone Marrow Transplant. 2015;50(9):1173-1179. doi:10.1038/bmt.2015.103
Dalle JH, Balduzzi A, Bader P, et al. Allogeneic stem cell transplantation from HLA-mismatched donors for pediatric patients with acute lymphoblastic leukemia treated according to the 2003 BFM and 2007 international BFM studies: impact of disease risk on outcomes. Biol Blood Marrow Transplant. 2018;24(9):1848-1855. doi:10.1016/j.bbmt.2018.05.009
Kumar A, Reljic T, Hamadani M, Mohty M, Kharfan-Dabaja MA. Antithymocyte globulin for graft-versus-host disease prophylaxis: an updated systematic review and meta-analysis. Bone Marrow Transplant. 2019;54(7):1094-1106. doi:10.1038/s41409-018-0393-0
Bacigalupo A, Lamparelli T, Bruzzi P, et al. Antithymocyte globulin for graft-versus-host disease prophylaxis in transplants from unrelated donors: 2 randomized studies from Gruppo Italiano Trapianti Midollo Osseo (GITMO). Blood. 2001;98(10):2942-2947. doi:10.1182/blood.v98.10.2942
Kebriaei P, Bassett R, Lyons G, et al. Clofarabine plus busulfan is an effective conditioning regimen for allogeneic hematopoietic stem cell transplantation in patients with acute lymphoblastic leukemia: long-term study results. Biol Blood Marrow Transplant. 2017;23(2):285-292. doi:10.1016/j.bbmt.2016.11.001